Which Country Is Aldurazyme (Laronidase) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Aldurazyme (laronidase) is a recombinant human alpha-L-iduronidase enzyme replacement therapy, developed under a partnership between BioMarin and Sanofi (Genzyme), approved for mucopolysaccharidosis I (MPS I), covering the Hurler, Hurler–Scheie and Scheie phenotypes. It is given as a weekly intravenous infusion to replace the deficient lysosomal enzyme that causes progressive accumulation of glycosaminoglycans in tissues throughout the body. Because MPS I is an ultra-rare condition, most countries have only a handful of treated patients at any time, and Aldurazyme is typically supplied through specialist metabolic-disease centres rather than general hospital pharmacy stock, which makes its pricing and availability far less transparent than for higher-volume biologics.

As an orphan drug for an ultra-rare disease, Aldurazyme is evaluated under different reimbursement pathways than mainstream oncology or immunology biologics: many health systems apply dedicated high-cost/orphan-drug funds or managed-access agreements rather than standard reference pricing, and in some countries it is supplied only on a named-patient or unlicensed-import basis where no local marketing authorisation is maintained. In Türkiye, TİTCK's external reference pricing framework, which tracks the lowest ex-factory price across a defined basket of EU countries using the fixed "pharmaceutical euro" (Dönemsel Avro Değeri), applies where the product is centrally authorised, as published on the TİTCK price list and gazetted in the Resmî Gazete, but named-patient supply for ultra-rare metabolic disease often sits outside that standard mechanism entirely.

The EMA's centralised procedure, mandatory for orphan medicines marketed across the EU, underpins Aldurazyme's licensed indication and is the reference point most national systems build their own assessment on (EMA). NICE in England and equivalent highly specialised technology processes weigh orphan drugs against a different, generally higher cost-effectiveness threshold than the standard £25,000–£35,000 QALY range that took effect from April 2026 (see NICE), reflecting the absence of alternative treatments for MPS I. The United States has no equivalent government reference mechanism, and OECD analysis of orphan-drug spending consistently finds ultra-rare-disease therapies priced and reimbursed on fundamentally different terms from mass-market biologics (OECD).

Because Aldurazyme is both hospital-infused and an orphan product for an ultra-rare disease, cross-country price comparisons are inherently harder to standardise than for common cancer or autoimmune biologics: published reference prices may not reflect confidential managed-access agreements, and in many countries supply depends on named-patient import authorised case-by-case by the national regulator rather than on a stocked, centrally reimbursed product. For the underlying mechanics of Türkiye's published prices, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Aldurazyme I'm being offered genuine?

No falsified batches of Aldurazyme have been recorded in WHO's alert series to date. That absence is not proof that any individual pack you are offered is genuine — it only means there is no documented incident to cite, and because Aldurazyme is often supplied through named-patient or unlicensed-import routes for an ultra-rare disease, the usual retail-pharmacy safeguards may not apply, which makes independent verification even more important, not less.

Because Aldurazyme is a weekly infusion typically coordinated through a specialist metabolic-disease centre, verification depends on that centre and its pharmacy checking the outer carton, the vial label, the batch number and the appearance of the solution before every single infusion — a falsified or mishandled vial reaching a patient who depends on lifelong weekly dosing carries particularly serious consequences given how few alternative treatments exist for MPS I.

• Scan the carton's GS1 DataMatrix and confirm it decodes to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch) matching the vial label exactly.
• If sourced in Türkiye, verify the karekod is registered on the national İlaç Takip Sistemi (İTS) track-and-trace system at its.saglik.gov.tr before administration; for named-patient imports without an İTS record, ask the treating centre what equivalent import documentation it holds.
• Ask for a continuous, unbroken 2–8°C temperature log covering the actual shipment you are receiving, not a generic cold-chain certificate — Aldurazyme must never be frozen or shaken.
• Before every weekly infusion, visually inspect the vial and diluted solution for particulate matter or discolouration, and check that the vial seal and label are intact and undamaged.
• Confirm the carton has not been opened and re-closed, and that the vial's tamper-evident seal shows no sign of having been broken and replaced.
• For named-patient or unlicensed-import supply, ask the treating specialist centre to confirm the product was sourced directly from BioMarin/Sanofi's authorised distribution chain and not from an unverified secondary supplier.
• Cross-check any batch you are uncertain about against our WHO falsified medicine alerts tracker and review our guide to checking that a medicine is genuine before the dose is administered.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Enzyme replacement therapies

Related high-cost medicines